gynaecological
No description yet: the sentence for this tag has not been written. 7 records carry it: 7 people.
7 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Amanda Nickles Fader Gynaecologic oncologist, Johns Hopkins · Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer. | p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer | none | endometrial, trialist | ||
Ana Oaknin Head of the Gynaecological Cancer Programme, Vall d'Hebron Institute of Oncology, Barcelona · Vall d'Hebron University Hospital / VHIO Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers. | Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Cervical cancer | none | endometrial, immunotherapy, trialist | ||
David M. Gershenson Gynaecologic oncologist, MD Anderson Cancer Center · MD Anderson Cancer Center Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it. | Low-grade serous ovarian cancer, Ovarian cancer | none | ovarian, trialist | ||
Krishnansu S. Tewari Gynaecologic oncologist, Chao Family Comprehensive Cancer Center, UC Irvine · Chao Family Comprehensive Cancer Center, UC Irvine California gynaecologic oncologist who led GOG 240, the trial that made bevacizumab the first targeted drug to lengthen survival in advanced cervical cancer, and EMPOWER-Cervical 1, which did the same for the PD-1 antibody cemiplimab. | Recurrent or metastatic cervical cancer, Cervical cancer | none | cervical, trialist | ||
Shannon N. Westin Gynaecologic oncologist, MD Anderson Cancer Center · MD Anderson Cancer Center Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer. | Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer | none | endometrial, trialist | ||
Susana Banerjee Consultant medical oncologist, The Royal Marsden and The Institute of Cancer Research · The Royal Marsden London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer. | Low-grade serous ovarian cancer, Ovarian cancer | none | ovarian, targeted-therapy, trialist | ||
Vicky Makker Gynaecologic medical oncologist, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy. | Advanced or recurrent endometrial cancer, Endometrial cancer | none | endometrial, immunotherapy, trialist |